SCHEMBL29797486

SCHEMBL29797486

CC(=O)c1ccc(F)cc1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 7/20 0.58
MAOA P21397 4/20 0.58
ALDH1A1 P00352 1/20 0.55
CYP3A4 P08684 1/20 0.55
HPGD P15428 1/20 0.55
MAPK1 P28482 1/20 0.55
CES2 O00748 2/20 0.48
CES1 P23141 2/20 0.48
CA3 P07451 1/20 0.48
CA6 P23280 1/20 0.48
CA5A P35218 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
CA5B Q9Y2D0 1/20 0.48
PRKDC P78527 1/20 0.45
HTT P42858 2/20 0.44
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MTOR P42345 1/20 0.43
P4HB P07237 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL537488 1.00 MAOB (0.58) MAOBMAOAALDH1A1CYP3A4HPGD
SCHEMBL31231917 0.83 P2RX1 (0.50) MAOBMAOAALDH1A1HPGDCES2
SCHEMBL467241 0.83 P2RX1 (0.50) MAOBMAOAALDH1A1HPGDCES2
SCHEMBL16508431 0.81 TTR (0.61) MAOBMAOAALDH1A1CYP3A4HPGD
SCHEMBL11570 0.80 CES2 (0.68) MAOBMAOACES2CES1HTT
SCHEMBL188203 0.80 ALDH1A1 (0.61) MAOBALDH1A1CYP3A4HPGDMAPK1
SCHEMBL29372550 0.80 CES2 (0.68) MAOBMAOACES2CES1HTT
SCHEMBL1121927 0.78 CES2 (0.48) MAOBMAOAALDH1A1CES2CES1
Hydrochloric Acid SCHEMBL5459426 0.78 ALDH1A1 (0.59) MAOBALDH1A1CYP3A4HPGDMAPK1
SCHEMBL1436288 0.78 MAPT (0.50) MAOBMAOAALDH1A1CYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122029177-A Oligonucleotides containing multiple ligands and/or lipids 阿达尔克斯制药有限公司 2026-05-12 CN disclosed
EP-4719593-A1 ENANTIOSELECTIVE PREPARATION METHOD Immunahr AB (SE) 2026-04-08 EP disclosed
EP-4712958-A2 USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Vandria SA (CH) 2026-03-25 EP disclosed
EP-4561976-A2 UROLITHIN AND FLUORENE DERIVATIVES FOR INHIBITING FERROPTOSIS Vandria SA (CH) 2025-06-04 EP disclosed
US-20250161459-A1 TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF ADARX PHARMACEUTICALS, INC. (US) 2025-05-22 US disclosed
CN-119948002-A Urolithin derivatives and therapeutic use 范徳利亚股份公司 2025-05-06 CN disclosed
WO-2025038963-A1 OLIGONUCLEOTIDES CONTAINING MULTIPLE LIGANDS AND/OR LIPIDS ADARX PHARMACEUTICALS, INC. (US) 2025-02-20 WO disclosed
CN-115867557-B Azepine condensed ring compound and medical application thereof 中国医药研究开发中心有限公司 2025-02-18 CN disclosed
EP-4475837-A2 TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF Adarx Pharmaceuticals, Inc. (US) 2024-12-18 EP disclosed
WO-2024245895-A1 ENANTIOSELECTIVE PREPARATION METHOD ANAMAR AB (SE) 2024-12-05 WO disclosed
CN-113727984-B Macrocyclic derivatives, preparation method and application thereof 浙江海正药业股份有限公司 2024-03-15 CN disclosed
WO-2024023585-A2 UROLITHIN DERIVATIVES AND THERAPEUTIC USES VANDRIA SA (CH) 2024-02-01 WO disclosed
WO-2024006287-A2 ANTIVIRAL COMPOUNDS USEFUL AGAINST SARS-COV-2 UNIVERSITY OF KANSAS (US) 2024-01-04 WO disclosed
CN-117304205-A Benzimidazole ternary fused ring compound, pharmaceutically acceptable salt thereof and application thereof 中国科学院广州生物医药与健康研究院 2023-12-29 CN disclosed
EP-3820869-B1 SPIROCHROMANE DERIVATIVES RICHTER GEDEON NYRT (HU) 2023-08-30 EP disclosed
WO-2023154896-A2 TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF ADARX PHARMACEUTICALS, INC. (US) 2023-08-17 WO disclosed
CN-109641864-B Anti-infective agents 邓迪大学 2023-04-04 CN disclosed
CN-115867557-A Azepine fused ring compounds and medical application thereof 中国医药研究开发中心有限公司 2023-03-28 CN disclosed
EP-3653613-B1 1,3-DI-SUBSTITUTED KETENE COMPOUND AND APPLICATION THEREOF BEBETTER MED INC (CN) 2022-11-16 EP disclosed
US-20220235070-A1 MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF SHANGHAI ARYL PHARMTECH CO., LTD. (CN) 2022-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235070-A1 MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF ROS1, IRAK1, IRAK2 MAOB 3018/4885MAOA 3553/4885ALDH1A1 3179/4885
US-20250161459-A1 TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF NTRK2, NTRK1, BDNF MAOB 265/4885MAOA 318/4885ALDH1A1 1653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.